Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

11. März 2026 09:15 ET | Quelle: Psyence Biomedical Ltd.

Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone

NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today reinforced how its strategic investment in PsyLabs strengthens its...
10. März 2026 08:00 ET | Quelle: GAUZY LTD

Gauzy Announces Initiation of a Call for Public Tenders for Buyers or Investors

Gauzy initiates public tender for buyers or investors as part of reorganization and appoints new board members to strengthen governance and support growth.
03. März 2026 09:15 ET | Quelle: Psyence Biomedical Ltd.

Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...
20. Februar 2026 17:20 ET | Quelle: Psyence Biomedical Ltd.

Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment

NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...
17. Februar 2026 09:15 ET | Quelle: Psyence Biomedical Ltd.

Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...
13. Februar 2026 18:30 ET | Quelle: Psyence Biomedical Ltd.

Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway

NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...
11. Februar 2026 09:15 ET | Quelle: Psyence Biomedical Ltd.

Psyence BioMed Announces Settlement of Shareholder Litigation

NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company") today announced that it has entered into a settlement agreement to resolve a...
10. Februar 2026 04:11 ET | Quelle: Research and Markets

1 Day UK Virtual Operational Resilience Preparedness & Compliance Training Course: Overview of FCA Operational Resilience, Ensuring Participants Leave with Practical Knowledge and Actionable Strategies

Dublin, Feb. 10, 2026 (GLOBE NEWSWIRE) -- The "Operational Resilience Preparedness & Compliance" training has been added to ResearchAndMarkets.com's offering.Are you Ready to Comply and Submit...
06. Februar 2026 08:03 ET | Quelle: GAUZY LTD

Gauzy Ltd. Announces Receipt of Nasdaq Notice Regarding Board Composition Requirements

Gauzy Ltd. announces receipt of a Nasdaq notice regarding continued listing requirements related to board composition
28. Januar 2026 18:30 ET | Quelle: Psyence Biomedical Ltd.

Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split

NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced the effective date of its 1-for-6.25 share consolidation...

Nächste Seite